ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
1541
Peringkat dalam Saham
#19248
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily... ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily dedicated to advancing immunotherapeutic treatments for various cancers. At the forefront of its development pipeline is IMM01, a CD47-targeting molecule currently undergoing clinical investigation. This lead candidate is being evaluated for its efficacy across a broad spectrum of malignancies, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), classical Hodgkin lymphoma (cHL), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinomas (HNSCC), and colorectal cancer (CRC). Beyond its primary program, the company boasts a robust portfolio of experimental therapies. These comprise IMM0306, a bispecific CD47×CD20 molecule aimed at relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL); IMM2902, another bispecific agent combining CD47 and HER2 for solid tumors that are either HER2-positive or HER2-low expressing; and IMM2520, a bispecific CD47×PD-L1 molecule intended for various solid tumors. Further development efforts include IMM47, a humanized monoclonal antibody designed to target CD24 for cancer treatment; MM4701, a distinct bispecific molecule simultaneously engaging both CD47 and CD24; IMM2510, a bispecific "mAb-Trap" engineered to block both VEGF and PD-L1; IMM27M, a CTLA-4 antibody enhanced for ADCC activity; and IMM40H, a humanized IgG1 CD70 monoclonal antibody also featuring augmented ADCC activity. The company was established in 2015 and is headquartered in Shanghai, China.
Harga Saham
$0.38122017
Terakhir disinkronkan: 2026-10-16
Kapitalisasi Pasar
$159.74M
Perubahan (1 hari)
2.58%
Perubahan (1 tahun)
-71.65%
Negara
CN
Perdagangan ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541)
Kategori
Healthcare
Kapitalisasi pasar dari ImmuneOnco Biopharmaceuticals (Shanghai) Inc.(1541)
Kapitalisasi Pasar: $159.74M
Per October 2026, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. memiliki kapitalisasi pasar sebesar $159.74M. Ini menjadikan ImmuneOnco Biopharmaceuticals (Shanghai) Inc. sebagai perusahaan 19248th paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar ImmuneOnco Biopharmaceuticals (Shanghai) Inc. dari 2023 hingga 2026
1541 dibandingkan dengan 5 teratas stocks paling populer
